Filter
28
Filtered Results: 28
Text search:
Food
and
Drug
Authority
(FDA),
Ghana
Featured
Recommendations
3
New Publications
12
Language
Document type
No document type
16
Studies & Reports
6
Guidelines
3
Manuals
2
Strategic & Response Plan
1
Countries / Regions
Ghana
13
Nigeria
2
Nepal
1
Rwanda
1
Malawi
1
Authors & Publishers
Publication Years
Category
Countries
12
Clinical Guidelines
2
Key Resources
2
Pharmacy & Technologies
2
Capacity Building
1
Toolboxes
AMR
5
Pharmacy
4
HIV
3
Rapid Response
2
COVID-19
2
Ebola
1
TB
1
Global Health Education
1
Document No. : FDA/SMC/SMD/GL-SMP/2015/05 |
These guidelines are for information, guidance and strict compliance by Marketing Authorization Holders and<...
Document No. : FDA/SMC/SMD/GL-RAR/2013/01
Document No. : FDA/SMC/CTD/GL-CCT/2013/01
This study addresses part of the Terms of Reference for a scoping report ‘An analysis of approaches to laboratory capacity strengthening for drug resistant infections in low and middle income coun...
The mandate of the National Tuberculosis Control Programme is to provide leadership and stewardship to accelerate intense and coordinated efforts to reduce the adult TB burden of 290 per 100,000 pop...
The Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) project has conducted a multi-year, multi-country study that provides stark insights on the under-reported depth of the antimicrobial resistance (AMR) crisis across Africa...
The Ghanaian Cabinet approved the antimicrobial resistance (AMR)Policy and Implementation plan(hereafter referred to as the national action plan or NAP)in December 2017, whilst the country case stu...
The WHO country office for Ghana, began the year 2019 with a 4-day staff retreat at the Busua Beach Resort in the Western Region from 04 to 08 March 2019. The theme for the retreat was ‘Impacting the Health ... Lives of the people of Ghana through the Triple Billion Goal”. The staff outlined priorities and strategies to strengthen WHO’s contribution to the national health agenda during the year. Working in collaboration with the Ministry of Health/Ghana Health Service and other allied health institutions and stakeholders, the WHO country office, provided support aimed at achieving its
mission which is attaining the highest level of health by the people in the country though its six operational areas which are (i) Communicable Diseases (ii) Non-Communicable Diseases, (iii) Promoting Health through the Life Course (iv), Health Systems, (v) Preparedness, Surveillance and Response (vi) Corporate services and enabling functions.
Due to the anticipated significant rise in VL testing occasioned by Ghana’s adaptation of 2016 ART guidelines, it has become necessary to develop this VL scale-up and operational plan to assure co...
The goal of this Global Action Plan is to articulate synergistic actions that will be required to prevent HIVDR from undermining efforts to achieve global targets on health and HIV, and to provide t...
The overall goal of the programme, to reduce the malaria morbidity and mortality by 75% (using 2012 as baseline) by the year 2020, continued to be pursued in 2014. The following areas were identified as some of the priorities for the year: Malaria C...
The WHO Pharmaceuticals Newsletter provides you with the latest information on the safety of medicinal products and regulatory actions taken by authorities around the world.
In addition, this edition includes summary ... recommendations from the virtual meeting of the members of the WHO Programme for International Drug Monitoring (PIDM) and other partners, which was held on 20 October 2022.
3rd edition
The most significant finding of the case study for integrating antimicrobial resistance (AMR)into existing programs and mobilising resources for funding in Nigeria, is that most of the AMR activities within the Nigerian National Actio...
The conduct of COVID-19 vaccine trials in the context of a candidate vaccine being issued with Emergency Use Designation raises challenging ethical questions, including in relation to the use of placebo controls and unblinding of trial participants ...
